De ClercqE: HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses, 1992; 8(2):119–134.
2.
DebouckC: The HIV protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses, 1992; 8(2):153–164.
3.
WildC, GreenwellT, and MatthewT: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses, 1993; 9(11):1051–1053.
4.
YoungB, SquiresKE, RossLL, SantiagoL, SloanLM, ZhaoHH, WineBC, PakesGE, MargolisDA, ShaeferMS, and the Aries EPZ108859 Study Team: Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses, 2013; 29(2):350–358.
5.
JansenK, SönnerborgA, BrockmeyerN, ThalmeA, SvedhemV, DupkeS, EychenneJL, NakonzT, Jimenez-ExpositoMJ, and PuglieseP: Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses, 2013; 29(3):564–573.
6.
AlbiniL, CalabresiA, GottiD, FerraresiA, FestaA, DonatoF, MagoniM, CastelliF, and Quiros-RoldanE: Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. AIDS Res Hum Retroviruses, 2013; 29(8):1097–1104.
7.
HsiehSM, PanSC, ChangSY, HungCC, ShengWH, ChenMY, and ChangSC: Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity. AIDS Res Hum Retroviruses, 2013; 29(8):1117–1122.
8.
ReynesJ, TrinhR, PulidoF, Soto-MalaveR, GatheJ, QaqishR, TianM, FredrickL, PodsadeckiT, NortonM, and NiliusA: Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses, 2013; 29(2):256–265.
9.
HütterG, NowakD, MossnerM, GanepolaS, MüssigA, AllersK, SchneiderT, HofmannJ, KüchererC, BlauO, BlauIW, HofmannWK, and ThielE: Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med, 2009; 360(7):692–698.
10.
YuklSA, BoritzE, BuschM, BentsenC, ChunTW, DouekD, EiseleE, HaaseA, HoYC, HütterG, JustementJS, KeatingS, LeeTH, LiP, MurrayD, PalmerS, PilcherC, PillaiS, PriceRW, RothenbergerM, SchackerT, SilicianoJ, SilicianoR, SinclairE, StrainM, WongJ, RichmanD, and DeeksSG: Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog, 2013; 9(5):e1003347.
11.
PersaudD, GayH, ZiemniakC, ChenYH, PiatakMJr, ChunTW, StrainM, RichmanD, and LuzuriagaK: Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med, 2013; 369(19):1828–1835.
12.
HenrichT, HanhauserE, SirignanoM, DavisB, LeeT-H, KeatingS, BuschM, MartyF, LaCasceA, ArmandP, SoifferR, AltfeldM, and KuritzkesD: In depth investigation of peripheral and gut HIV-1 reservoirs, HIV-specific cellular immunity, and host microchimerism following allogeneic hematopoetic stem cell transplantation. International AIDS Society conference, 2013, WELBA05.
13.
JosefssonL, von StockenstromS, FariaNR, SinclairE, BacchettiP, KillianM, EplingL, TanA, HoT, LemeyP, ShaoW, HuntPW, SomsoukM, WylieW, DouekDC, LoebL, CusterJ, HohR, PooleL, DeeksSG, HechtF, and PalmerS: The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. PNAS, 2013; 110(51):E4987–E4996.
14.
ErikssonS, GrafEH, DahlV, StrainMC, YuklSA, LysenkoES, BoschRJ, LaiJ, ChiomaS, EmadF, Abdel-MohsenM, HohR, HechtF, HuntP, SomsoukM, WongJ, JohnstonR, SilicianoRF, RichmanDD, O'DohertyU, PalmerS, DeeksSG, and SilicianoJD: Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog, 2013; 9(2):e1003174.
15.
ShanL, DengK, ShroffNS, DurandCM, RabiSA, YangHC, ZhangH, MargolickJB, BlanksonJN, and SilicianoRF: Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity, 2012; 36(3):491–501.
16.
HoYC, ShanL, HosmaneNN, WangJ, LaskeySB, RosenbloomDI, LaiJ, BlanksonJN, SilicianoJD, and SilicianoRF: Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell, 2013; 155(3):540–551.
17.
[No authors listed]: AIDS vaccine 2013 October 7–10, 2013 Barcelona, Spain. AIDS Res Hum Retroviruses, 2013; 29(11):A1–A208.
18.
KarasavvasN, BillingsE, RaoM, WilliamsC, Zolla-PaznerS, BailerRT, KoupRA, MadnoteS, ArwornD, ShenX, TomarasGD, CurrierJR, JiangM, MagaretC, AndrewsC, GottardoR, GilbertP, CardozoTJ, Rerks-NgarmS, NitayaphanS, PitisuttithumP, KaewkungwalJ, ParisR, GreeneK, GaoH, GurunathanS, TartagliaJ, SinangilF, KorberBT, MontefioriDC, MascolaJR, RobbML, HaynesBF, NgauyV, MichaelNL, de KimJH, SouzaMS, and the MOPH TAVEG Collaboration. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses, 2012; 28(11):1444–1457.
19.
KlassePJ, SandersRW, CeruttiA, and MooreJP: How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?. AIDS Res Hum Retroviruses, 2012; 28(1):1–15.
20.
KiserPF, MesquitaPM, and HeroldBC: A perspective on progress and gaps in HIV prevention science. AIDS Res Hum Retroviruses, 2012; 28(11):1373–1378.
21.
National Institute of Allergy and Infectious Diseases, Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention, July20, 2001.
22.
CohenJ: Miracle on 34th Street: Success with injectors. Science, 2012; 337(6091):178–180.
23.
BaetenJM, HabererJE, LiuAY, and SistaN: Preexposure prophylaxis for HIV prevention: Where have we been and where are we going?. J Acquir Immune Defic Syndr, 2013; 63(Suppl 2):S122–129.
24.
Abdool KarimQ, Abdool KarimSS, FrohlichJA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010; 329:1168–1174.
25.
CohenMS, ChenYQ, McCauleyM, GambleT, HosseinipourMC, KumarasamyN, HakimJG, KumwendaJ, GrinsztejnB, PilottoJH, GodboleSV, MehendaleS, ChariyalertsakS, SantosBR, MayerKH, HoffmanIF, EshlemanSH, Piwowar-ManningE, WangL, MakhemaJ, MillsLA, de BruynG, SanneI, EronJ, GallantJ, HavlirD, SwindellsS, RibaudoH, ElharrarV, BurnsD, TahaTE, Nielsen-SainesK, CelentanoD, EssexM, FlemingTR, and the HPTN 052 Study Team: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011; 365(6):493–505.
